Bioceres 20-F: Going-Concern Doubt, $263.9M FY26 Loss, $110.1M Noteholder Judgment
BIOX is trading near its 52-week low of $0.19 (9.5% above the low) on light trading volume (0.4× avg).
Summary
Bioceres' audited FY2026 annual report discloses substantial doubt about its ability to continue as a going concern, with $11.2 million of cash against $229.2 million of debt and a $110.1 million noteholder judgment on appeal.
Key Events · Legal and Risk Events · BIOX
-
Going-Concern Warning in Audited Accounts
The FY2026 financial statements state that uncertainty over securing additional financing raises substantial doubt about the company's ability to continue as a going concern.
-
Cash of $11.2M Against $229.2M Debt
Total indebtedness was $229.2 million at June 30, 2026, with $169.2 million maturing in fiscal 2027, including $122.0 million of accelerated Secured Notes; current liabilities exceeded current assets by $54.9 million.
-
$110.1M Judgment on Appeal
On October 2, 2026, the New York court entered a $110.1 million judgment plus $1.4 million of fees and costs; Bioceres has appealed to the Appellate Division, First Department.
-
Pro Farm Foreclosure Drives $263.9M Loss
The January 2026 foreclosure produced a $181.3 million loss, taking the full-year net loss to $263.9 million on revenue of $238.3 million, down 18% from $289.4 million.
Analysis · BIOX · Industrial Applications And Services
Audited accounts now carry going-concern language: management states that uncertainty over securing additional financing raises substantial doubt about the company's ability to continue. Cash stands at $11.2 million against $229.2 million of debt, of which $169.2 million falls due within fiscal 2027, including $122.0 million of Secured Notes that were accelerated and are now the subject of a $110.1 million judgment on appeal. The Pro Farm foreclosure has already cost the company its U.S. and European biologicals business, booked as a $181.3 million loss, and revenue from what remains fell 18% to $238.3 million. The path forward runs through a settlement or restructuring with the noteholders plus new financing or asset sales, none of which is assured.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 49% of the 206 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.93%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIOX was trading at $0.21 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $0.19 to $2.10. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.